Lodi

Researchers are studying children hospitalized with bronchiolitis to compare two different strategies aimed at improving follow-up care after hospital discharge. The study focuses on increasing the use of as-needed follow-up visits prescribed by hospital physicians and reducing unnecessary routine follow-up visits, which research has shown are often not needed. This trial evaluates how these strategies may impact care and family experience for young children recovering from bronchiolitis. The study compares a moderate-resource implementation strategy with a high-resource implementation strategy. The moderate approach includes educational outreach with materials for families, clinician performance reviews, and clinical decision support tools. The high-resource strategy adds small-group facilitation and expert coach-led support to the components of the moderate strategy. These strategies are designed to encourage appropriate follow-up care decisions by hospitalists. Participants are children diagnosed primarily with bronchiolitis, discharged from general inpatient care outside intensive or emergency settings. Researchers will measure how often as-needed follow-up is prescribed and sustained within seven days after hospital discharge. Families attendance at follow-up visits will be tracked to assess if unnecessary visits decrease. The study will monitor outcomes related to follow-up care practices and their impact through the hospital stay and shortly after discharge, with participation lasting through the immediate post-hospital period.

Researchers are evaluating whether a new medicine called PF-08634404, given with chemotherapy, works better than the current standard treatment of pembrolizumab combined with chemotherapy for adults with a type of lung cancer known as non-small cell lung cancer NSCLC. This study focuses on participants with locally advanced or metastatic NSCLC who are not candidates for surgery or curative chemoradiotherapy and have no known actionable genomic alterations. The study is a Phase 3 randomized trial with double-blind masking to compare these treatments. Participants are assigned to one of two parts based on their tumor type those with squamous NSCLC are in Part 1, and those with non-squamous NSCLC are in Part 2. Each participant is randomly placed into one of two treatment groups the experimental group receives PF-08634404 plus chemotherapy, while the control group receives pembrolizumab plus chemotherapy. Treatments are given through intravenous infusions in cycles, followed by maintenance therapy with either PF-08634404 or pembrolizumab, depending on the part of the study. Participants continue treatment as long as it helps and side effects are manageable. During the study, participants attend regular visits for treatment and health assessments. Cancer response is checked every 6 weeks for the first 48 weeks and then every 12 weeks after that. Researchers monitor overall survival, progression-free survival, objective response rates, duration of response, adverse events, lab abnormalities, and quality of life measures. The study includes detailed tracking of drug levels and immune responses. Participation may last up to approximately 39 months, with continuous safety and effectiveness monitoring.